The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2023
Filed:
Jul. 16, 2021
Applicant:
Roche Innovation Center Copenhagen A/s, Hørsholm, DK;
Inventors:
Nanna Albæk, Hørsholm, DK;
Maj Hedtjärn, Hørsholm, DK;
Marie Wickstrom Lindholm, Hørsholm, DK;
Niels Fisker Nielsen, Hørsholm, DK;
Andreas Petri, Hørsholm, DK;
Jacob Ravn, Hørsholm, DK;
Assignee:
ROCHE INNOVATION CENTER COPENHAGEN A/S, Hørsholm, DK;
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 47/54 (2017.01); A61K 31/712 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 47/545 (2017.08); A61K 47/549 (2017.08); A61K 47/554 (2017.08); C12N 15/113 (2013.01); A61K 31/712 (2013.01); C12N 2310/11 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01); C12N 2330/30 (2013.01);
Abstract
The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.